Watch FDA Layoffs and the Impact to Industry now.
Recent changes at the FDA are expected to have a major impact on review capacity and expertise, with some therapy areas hit harder than others. MCRA’s regulatory experts will share their insight on impact to specific OPEQ review teams and OSEL technical areas as well as how they expect these changes will impact industry moving forward. MCRA experts will also provide strategic recommendations for how to react, adjust and most successfully move forward with your regulatory plans.
- Recent FDA layoffs expected to have major impact on review timelines and priorities
- MCRA will share understanding impact to review teams and technical areas
- MCRA will provide recommendations to industry for how to most successfully react & adjust to recent FDA changes
This webinar was recorded on Monday, March 17th, 2025.
Moderator:
Margeaux Rogers, MS, RAC - VP, Spine Regulatory Affairs
Panelists:
Alex Cadotte, Ph.D. - VP, Digital Health, AI, and Radiology Regulatory Affairs
Former FDA Team Lead, Mammography, Ultrasound & Imaging Software
Devjani Saha, Ph.D. - Director, Neurology Regulatory Affairs
Former FDA Regulatory Reviewer and Clinical Trials Policy Analyst
Eric Sussman, Ph.D. - Director, Biocompatibility
Former FDA Biomedical Engineer & Regulatory Reviewer